Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 2, 2008, Pages 121-127

  Afify, Alaa ^a,c   McNiel, Maaya A ^a   Braggin, Jacquelyn ^a   Bailey, Helen ^a   Paulino, Augusto F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Genzyme Genetics ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD44s; CD44v6, breast cancer; Hyaluronan

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID; PARAFFIN;

ANTIGEN EXPRESSION; ARTICLE; BREAST; BREAST CARCINOMA; BREAST DISEASE; BREAST EPITHELIUM; BREAST HYPERPLASIA; BREAST STROMA; CANCER GROWTH; CORRELATIONAL STUDY; DISEASE COURSE; EPITHELIUM CELL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MYOEPITHELIUM CELL; PATHOLOGY; PRIORITY JOURNAL; SPECTRUM; STROMA CELL; TISSUE SECTION; BREAST TUMOR; CHEMISTRY; FEMALE; HYPERPLASIA; METABOLISM;

ANTIGENS, CD44; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; HYALURONIC ACID; HYPERPLASIA;

EID: 46749130570     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318047df6d     Document Type: Article

References (48)

1. American Cancer Society. Breast Cancer Facts & Figures, Statistic. 2005.
2. Toole BP. Glycosaminoglycans in morphogenesis. In: Hay E, ed. Cell Bio Extracell Matrix. New York: Plenum Press; 1991: 1384-1386.
3. Weigel H, Fuller M, Le Boeuf R. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J Theor Biol. 1986;119:219-234.
4. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J. 1993;J7: 1233-1241.
5. Toole BP, Hascall VC. Hyaluronan and tumor growth. Am J Pathol. 2002;161:745-747.
6. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology. 2002;12:37-42.
7. Hayen W, Goebeler M, Kumar S, et al. Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. J Cell Sci. 1999;112:2241-2251.
8. Simpson MA. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am J Pathol. 2006;169:247-257.
9. Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol. 2002; 161:849-857.
10. Evanko SP, Wight TN. Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem. 1999;47:1331-1342.
11. Underhill C. CD44: the hyaluronan receptor. J Cell Sci. 1992;103: 293-298.
12. Tolg C, Hoffman M, Herrlich P. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res. 1993;21: 1225-1229.
13. Auvinen P, Tammi R, Tammi M, et al. Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology. 2005;47:420-428.
14. Ripellin JA, Klinger MM, Margolis RU. The hyaluronic acid binding region as a specific probe for the localization of hyaluronic acid in tissue sections. J Histochem Cytochem. 1985;33:1060-1066.
15. Zhang L, Underhill C, Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res. 1995;55: 428-433.
16. Kimata K, Honma Y, Okayama M, et al. Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential. Cancer Res. 1983;43:1347-1354.
17. Bertrand P, Girard N, Delpech B, et al. Hyaluronan and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer. 1992;52:1-6.
18. Ponting J, Kumar S, Pye D. Co-localisation of hyaluronan and hyaluronectin in normal and neoplastic breast tissues. Int J Oncol. 1993;2:889-893.
19. Corte MD, Gonzalez LO, Lamelas ML, et al. Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res Treat. 2006;97:329-337.
20. Wernicke M, Pineiro LC, Caramutti D, et al. Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod Pathol. 2003;16:99-107.
21. Suwiwat S, Ricciardelli C, Tammi R, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res. 2004;10: 2491-2498.
22. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell Biol. 1990;2:839-844.
23. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol. 1993;54:271-335.
24. Antonelli A, D'Amore PA. Density-dependent expression of hyaluronic acid binding to vascular cells in vitro. Microvasc Res. 1991;41:239-251.
25. Bose N, Masellis AM. Secretory products of breast cancer cells upregulate hyaluronan production in a human osteoblast cell line. Clin Exp Metastasis. 2005;22:629-642.
26. Edward M, Gillan C, Micha D, et al. Tumor regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumor growth and invasion. Carcinogenesis. 2005;26:1215-1223.
27. Culty M, Nguyen HA, Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol. 1992;116:1055-1062.
28. Sato E, Tanaka T. Ovarian glycosaminoglycans potentiate angiogenic activity of epidermal growth factor in mice. Endocrino. 1991;128:2402-2406.
29. West DC, Hampson IN, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985;228:1324-1326.
30. Schneider J, Pollan M, Ruibal A, et al. Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer. Tumor Biol. 1999;20:319-330.
31. Bankfalvi A, Terpe HJ, Breukelmann D. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology. 1998;33:107-116.
32. Berner HS, Suo Z, Risberg B, et al. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology. 2003;42:546-556.
33. Lyzak JS, Yaremko ML, Recant W, et al. Role of CD44 in nonpalpable T1a and T1b breast cancer. Hum Pathol. 1997;28: 772-778.
34. Sugahara KN, Murai T, Nishinakamura H, et al. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem. 2003;278: 32259-32265.
35. Okamoto I, Tsuiki H, Kenyon LC, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002;160:441-447.
36. Matsuki H, Yonezawa K, Obata K. Monoclonal antibodies with defined recognition sequences in the stem region of CD44: detection of differential glycosylation of CD44 between tumor and stromal cells in tissue. Cancer Res. 2003;63:8278-8283.
37. Afify AM, Craig S, Paulino AFG. The temporal variation in the distribution of hyaluronic acid, CD44s and CD44v6 in human endometrium across the menstrual cycle. Appl Imm Mol Morph. 2005;14:328-333.
38. Rodrigo JP, Dominguez F, Alvarez C, et al. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002;118:67-72.
39. Wielenga VJ, Heider KH, van den Berg FM, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754-4756.
40. Afify A, Craig S, Stern R, et al. Expression of hyaluronic acid and its receptors, CD44, CD44v6 in normal, hyperplastic and neoplastic endometrium. Ann Diagn Pathol. 2005;9:312-318.
41. Afify A, Ferguson AW, Davila RM, et al. Expression of CD44S and CD44v5 is more common in Stage III than in Stage I serous ovarian carcinomas. Appl Imm Mol Morph. 2001;9:309-314.
42. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13-24.
43. Guo Y, Ma J, Wang J. Inhibition of human-melanoma growth and metastasis in-vivo by anti-CD44 monoclonal-antibody. Cancer Res. 1994;54:1561-1565.
44. Bourguignon L, Zhu H, Shao L, et al. Ankyrin-Tiam1 Interaction Promotes Rac1 Signaling and Metastatic Breast Tumor Cell Invasion and Migration. J Cell Biol. 2000;150:177-191.
45. Bourguignon LY, Zhu H, Shao L, et al. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275:1829-1838.
46. Bourguignon L, Zhu HB, Chu A, et al. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem. 1997;272:27913-27918.
47. Colnot DR, Quak JJ, Roos JC, et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med. 2000;41:1999-2010.
48. Karl-Heinz H, Hartmut K, Gerd S, et al. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004;53:567-579.